<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02186080</url>
  </required_header>
  <id_info>
    <org_study_id>H-1401-089-550</org_study_id>
    <nct_id>NCT02186080</nct_id>
  </id_info>
  <brief_title>Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia</brief_title>
  <official_title>Evaluation of the Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia Induced by High Fat Diet in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory study on the metabolic endotoxemia associated with type 2 diabetes.
      The investigators will measure systemic endotoxin level and lipid level after ingestion of
      high fat diet to evaluate the effect of gemigliptin, a DPP-4 inhibitor, on metabolic
      endotoxemia and lipemia induced by high fat diet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study subjects will be allocated to either gemigliptin or placebo. After 4 weeks of treatment
      and 2 weeks of wash out period, all subjects will be switched to the opposite arm.

      The subjects will be tested oral fat tolerance test and adipose tissue needle biopsy(only for
      the subjects who agreed to participate donate adipose tissue) at 3 time points: the start of
      1st treatment, end of 1st treatment and end of 2nd treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between baseline and peak serum LPS</measure>
    <time_frame>serum LPS before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet</time_frame>
    <description>The increment of serum LPS after ingestion of high fat diet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting serum LPS level</measure>
    <time_frame>After 10 hrs of fasting</time_frame>
    <description>Compare fasting LPS level between treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental AUC of serum LPS during oral fat tolerance test</measure>
    <time_frame>serum LPS before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet</time_frame>
    <description>Calculated incremental AUC of serum LPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between baseline and peak serum triglyceride level</measure>
    <time_frame>serum TG before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet</time_frame>
    <description>The increment of serum TG after ingestion of high fat diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental AUC of serum triglyceride level during oral fat tolerance test</measure>
    <time_frame>serum TG before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet</time_frame>
    <description>Calculated incremental AUC of serum TG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between baseline and peak serum apolipoprotein-B48</measure>
    <time_frame>serum apolipoprotein-B48 before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet</time_frame>
    <description>The increment of serum apolipoprotein-B48 after ingestion of high fat diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental AUC of serum apolipoprotein-B48 during oral fat tolerance test</measure>
    <time_frame>serum apolipoprotein-B48 before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet</time_frame>
    <description>Calculated incremental AUC of serum apolipoprotein-B48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum level of inflammatory markers (CRP, TNF-alpha, IL-6)</measure>
    <time_frame>After 10 hr of fasting</time_frame>
    <description>Compare serum level of inflammatory markers between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression level of inflammatory markers in the adipose tissue</measure>
    <time_frame>After high fat diet ingestion</time_frame>
    <description>Compare mRNA expression level of inflammatory markers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Gemigliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemigliptin 50mg qd added to subjects current diabetes treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (identical in appearance to gemigliptin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin</intervention_name>
    <arm_group_label>Gemigliptin</arm_group_label>
    <other_name>Zemiglo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 20 to 75

          -  At least 6 months from the diagnosis of type 2 diabetes

          -  Current diabetes treatment: life style modification and/or metformin and/or
             sulfornylurea

          -  No change of the diabetes treatment (drug number and dossage) in recent 3 months

          -  HbA1c 6.5% to 10%

        Exclusion Criteria:

          -  Recent cardiovascular event in 6 months

          -  Concurrent use of statin or fibrate or ezetimibe

          -  Renal failure, chronic liver disease

          -  Pregnancy or lactation

          -  Use of other DPP-4 inhibitor or GLP-1 analogue in recent 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Min Cho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2014</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>metabolic endotoxemia</keyword>
  <keyword>gemigliptin</keyword>
  <keyword>DPP-4 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Endotoxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

